New approach has potential to cure pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) affects 200, 000 people annually and there is no cure for this condition.  Researchers at Indiana University and University of Illinois at Chicago, have identified a potential drug for curing PAH. The drug, DGMS-RAR7, has shown efficacy in animal models of pulmonary hypertension and has a new mode of action compared to current PAH drugs on the market. The drug is further being developed by Drax Therapeutic Inc., an Indiana-based small business co-founded by Dr. Roberto Machado (Indiana University) and Dr. Tom Driver (UIC). Drax is looking for a CEO, industry partners and investors to advance the technology to the clinic.